Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers

Mathematical Biosciences

Volumn 240, Issue 1, 2012, Pages 20-34

  Hazelton, William D ^a   Goodman, Gary ^a   Rom, William N ^b   Tockman, Melvyn ^c   Thornquist, Mark ^a   Moolgavkar, Suresh ^a   Weissfeld, Joel L ^d   Feng, Ziding ^a  

^a USA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

CT screening; Longitudinal model; Lung cancer; Multistage

Indexed keywords

ASBESTOS EXPOSURE; COMPUTERIZED TOMOGRAPHY SCREENING; CURE RATE; DIAGNOSIS OF LUNG CANCER; GENDER DIFFERENCES; GOMPERTZ GROWTH; IMMUNE SYSTEMS; LONGITUDINAL ANALYSIS; LOW DOSE; LUNG CANCER; LUNG CANCER MORTALITY; MODEL CALIBRATION; MULTI-STAGE MODELS; MULTISTAGE; NEW YORK UNIVERSITY; PITTSBURGH; SPIRAL CT;

BIOLOGICAL ORGANS; CALIBRATION; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; HEALTH HAZARDS;

DISEASES;

CANCER; MODELING; MORTALITY; SMOKING; TOMOGRAPHY;

ADULT; ARTICLE; CALIBRATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MEDICAL HISTORY; PROBABILITY; SEX DIFFERENCE; SMOKING; STATISTICAL MODEL;

FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEW YORK; PENNSYLVANIA; SEX FACTORS; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864743952     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2012.05.008     Document Type: Article

References (51)

1. B.A. Kohler, E. Ward, B.J. McCarthy, M.J. Schymura, L.A.G. Ries, C. Eheman, A. Jemal, R.N. Anderson, U.A. Ajani, B.K. Edwards, Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. JNCI. 103(9) (2011) p. 714.
2. W.N. William Jr., H.Y. Lin, J.J. Lee, S.M. Lippman, J.A. Roth, E.S. Kim, Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. Sep;13 6(3) (2009) p. 701. Epub 2009 Mar 24.
3. Rami-Porta R., Crowley J.J., Goldstraw P. The revised TNM staging system for lung cancer. Ann. Thorac. Cardiovasc Surg. 2009, 15(1):4. PMID: 19262443.
4. Greenwald P. A favorable view: progress in cancer prevention and screening. Recent Results Cancer Res. 2007, 174:3.
5. Aberle D.R., Berg C.D., Black W.C. National lung screening trial research team. The national lung screening trial: overview and study design. Radiology 2011, 259:243.
6. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. National lung screening trial research team, reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365(5):395. Aug 4.
7. P.B. Bach, J.R. Jett, U. Pastorino, M.S. Tockman, S.J. Swensen, C.B. Begg, Computed tomography screening and lung cancer outcomes, JAMA. 2007 Mar 7, 297 (9) p. 953. Erratum in: JAMA. 2007 Aug 1;298(5):518.
8. W.M. Alberts, American College of Chest Physicians. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition), Chest. 2007 Sep; 132 (3) Suppl: 1S-19S.
9. J.M. Reich, A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax., Apr 63(4) (2008) p. 377.
10. Hillerdal G. Indolent lung cancers - time for a paradigm shift: a review. J. Thorac. Onco. 2008, 3(3):208. Mar.
11. Hakama M., Holli K., Visakorpi T., Pekola M., Kallioniemi O.P. Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. Int. J. Cancer 1996, 66(1):6. Mar 28.
12. Hasegawa M., Sone S., Takashima S., Li F., Yang Z.G., Maruyama Y., Watanabe T. Growth rate of small lung cancers detected on mass CT screening. Br. J. Radiol. 2000, 73(876):1252. Dec.
13. Sone S., Li F., Yang Z.G., Honda T., Maruyama Y., Takashima S., Hasegawa M., Kawakami S., Kubo K., Haniuda M., Yamanda T. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br. J. Cancer 2001, 84(1):25. Jan 5.
14. R.M. Lindell, T.E. Hartman, S.J. Swensen, J.R. Jett, D.E. Midthun, J.N. Mandrekar, 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest. Dec;136 (6) (2009) p. 1586.
15. Diggle P.J., Heagerty P.J., Liang K.-Y., Zeger S.L. Analysis of Longitudinal Data 2003, Oxford University Press Inc., New York, Second edition.
16. Moolgavkar S.H., Knudson A.G. Mutation and cancer: a model for human carcinogenesis. J. Nat. Cancer Inst. 1981, 66(6):1037. Jun.
17. Moolgavkar S.H., Luebeck E.G. Two-event model for carcinogenesis: biological, mathematical and statistical considerations. Risk Anal. 1990, 10:323.
18. R. Meza, W.D. Hazelton, G.A. Colditz, S.H. Moolgavkar, Analysis of lung cancer incidence in the nurses' health and the health professionals' follow-up studies using a multistage carcinogenesis model, Cancer Causes Control., Dec 6, 2007. doi:10.1007/s10552-007-9094-5.
19. Fakir H., Hofmann W., Sachs R.K. Modeling progression in radiation-induced lung adenocarcinomas. Radiat. Environ. Biophys. 2010, 49(2):169. May.
20. Jeon J., Meza R., Moolgavkar S.H., Luebeck E.G. Evaluation of screening strategies for pre-malignant lesions using a biomathematical approach. Math. Biosci. 2008, 213(1):56. May.
21. P.M. McMahon, C.Y. Kong, B.E. Johnson, M.C. Weinstein, J.C. Weeks, K.M. Kuntz, J.A. Shepard, S.J. Swensen, G.S. Gazelle, Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. Jul; 248(1) (2008) p. 278. Epub 2008 May 5.
22. M.A.Pashkevich, B.M. Sigal, S.K. Plevritis, Modeling the transition of lung cancer from early to advanced stage, Cancer Causes Control, November 2009, 20(9) (2009) p. 1559. Epub 2009 Jul 23.PMID: pmid:19629730.
23. H. Putter, T. Vos, H. de Haes, H. van Houwelingen, Joint analysis of multiple longitudinal outcomes: application of a latent class model, Stat Med. December 2008, 20;27(29) 2008 p. 6228. PMID: pmid:18816496.
24. Baker S.G., Tockman M.S. Evaluating serial observations of precancerous lesions for further study as a trigger for early intervention. Stat Med. 2002, 21(16):2383. Aug 30.
25. Lee M.L., Whitmore G.A., Rosner B.A. Threshold regression for survival data with time-varying covariates. Stat Med. 2010, 29(7-8):896. Mar 30.
26. R.J. van Klaveren, S.C. van't Westeinde, B.J. de Hoop, H.C. Hoogsteden, Stem cells and the natural history of lung cancer: implications for lung cancer screening, Clin. Cancer Res. April 2009, 1,15(7) (2009) p. 2215. Epub 2009 Mar 17.
27. G.S. Omenn, G. Goodman, J. Grizzle, M. Thornquist, L. Rosenstock, S. Barnhart, G. Anderson, J. Balmes, M. Cherniack, J. Cone, et al. CARET, The beta-carotene and retinol efficacy trial to prevent lung cancer in asbestos-exposed workers and in smokers. Anticancer Drugs. Feb; 2(1) (1991) p. 79.
28. Wilson D.O., Weissfeld J.L., Fuhrman C.R., Fisher S.N., Balogh P., Landreneau R.J., Luketich J.D., Siegfried J.M. The pittsburgh lung screening study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am. J. Respir. Crit. Care Med. 2008, 178(9):956. Nov 1.
29. Tan W.Y. Stochastic models of carcinogenesis 1991, Marcel Dekker, New York.
30. Allen L.J.S. An introduction to stochastic processes with applications to biology 2003, Prentice Hall, Upper Saddle River, New Jersey.
31. Quinn D.W. The method of characteristics applied to a stochastic two-stage model of carcinogenesis. Math. Comput. Model. 1997, 25(7):1. April.
32. Harris T.E. The theory of branching processes. Applied Mathematics Series 1963, Elglewood Cliffs, Prentice-Hall, NJ.
33. Crump K.S., Subramaniam R.P., Van Landingham C.B. A numerical solution to the nonhomogeneous two-stage MVK model of cancer. Risk Anal. 2005, 25(4):921. Aug.
34. Geddes D.M. The natural history of lung cancer: a review based on rates of tumour growth. Br. J. Dis. Chest. 1979, 73(1):1. Jan.
35. Tan W.Y. A stochastic Gompertz birth-death process. Stat. Prob. Lett. 1986, 4:258.
36. Luebeck E.G., Moolgavkar S.H. Stochastic analysis of intermediate lesions in carcinogenesis experiments. Risk Anal. 1991, 11(1):149. Mar.
37. A.Dewanji, E.G. Luebeck, S.H. Moolgavkar, A generalized Luria-Delbrck model, Math Biosci., Oct;197(2) (2005) p.140.
38. Bach P.B., Kattan M.W., Thornquist M.D., Kris M.G., Tate R.C., Barnett M.J., Hsieh L.J., Begg C.B. Variations in lung cancer risk among smokers. J. Natl. Cancer Inst. 2003, 95(6):470. Mar 19.
39. Hindmarsh A.C. ODEPACK - a systematized collection of ODE solvers. Scientific Computing of IMACS Transactions on Scientific Computation 1983, 1:55. North-Holland, Amsterdam.
40. G. Luebeck, Package 'Bhat'., 2009. Accessed 11/10/2010. http://cran.r-project.org/web/packages/Bhat/Bhat.pdf.
41. Kalbfleisch J.D., Prentice R.L. The Statistical Analysis of Failure Time Data 1980, John Wiley and Sons, New York.
42. A.E. Bishop, Pulmonary epithelial stem cells, Cell Prolif. Feb; 37(1) (2004) p. 89. Review.
43. Mercer R.R., Russell M.L., Roggli V.L., Crapo J.D. Cell number and distribution in human and rat airways. Am. J. Respir. Cell Mol. Biol. 1994, 10(6):613. Jun.
44. Boers J.E., Ambergen A.W., Thunnissen F.B. Number and proliferation of basal and parabasal cells in normal human airway epithelium. Am. J. Respir. Crit. Care Med. 1998, 157. Jun;(6 Pt 1):2000-6.
45. J.E. Boers, A.W. Ambergen, F.B. Thunnissen, Number and proliferation of clara cells in normal human airway epithelium, Am. J. Respir. Crit. Care Med. 1999 May;159(5 Pt 1) p. 1585.PMID: pmid:10228131.
46. Hall E., Giaccia A. Radiobiology for the radiologist 2006, Lippincott Williams and Wilkins. Edition 6.
47. Day N.E., Walter S.D. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984, 40(1):1. Mar.
48. Gulati R., Inoue L., Katcher J., Hazelton W., Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010, 11(4):707. Oct.
49. Havrilesky L.J., Sanders G.D., Kulasingam S., Chino J.P., Berchuck A., Marks J.R., Myers E.R. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer. 2011, 117(3):545. Feb 1. 10.1002/cncr.25624.
50. S.A. Frank, M.A. Nowak, Cell biology: developmental predisposition to cancer, Nature, Apr 3; 422(6931) (2003) 494. No abstract available. PMID: pmid:12673242.
51. R. Meza, E.G. Luebeck, S.H. Moolgavkar. Gestational mutations and carcinogenesis. Math Biosci., Oct; 197(2) (2005) p. 188. PMID: pmid:16087198.